{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:59:14Z","timestamp":1787007554230,"version":"build-2736575974"},"reference-count":38,"publisher":"Informa UK Limited","issue":"5","license":[{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"BeOne Medicines, Ltd"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Hematology"],"published-print":{"date-parts":[[2026,5,4]]},"DOI":"10.1080\/17474086.2026.2628534","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T22:14:07Z","timestamp":1770761647000},"page":"539-546","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Real-world treatment utilization patterns, discontinuation and healthcare resource utilization of first-line Bruton tyrosine kinase inhibitors among elderly patients \u226565\u2009years in chronic lymphocytic leukemia"],"prefix":"10.1080","volume":"19","author":[{"given":"Sikander","family":"Ailawadhi","sequence":"first","affiliation":[{"name":"Mayo Clinic","place":["Jacksonville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swetha","family":"Challagulla","sequence":"additional","affiliation":[{"name":"BeOne Medicines Ltd","place":["San Carlos, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Ya","family":"Chuang","sequence":"additional","affiliation":[{"name":"Real Chemistry","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley","family":"Furnback","sequence":"additional","affiliation":[{"name":"Real Chemistry","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keri","family":"Yang","sequence":"additional","affiliation":[{"name":"BeOne Medicines Ltd","place":["San Carlos, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,2,14]]},"reference":[{"key":"#cr-split#-e_1_3_7_2_1.1","unstructured":"American Cancer Society. Key statistics for chronic lymphocytic leukemia (CLL) 2025. [updated 2025 Mar 20"},{"key":"#cr-split#-e_1_3_7_2_1.2","unstructured":"cited 2025 Aug 5]. updated https:\/\/www.cancer.org\/cancer\/types\/chronic-lymphocytic-leukemia\/about\/key-statistics.html#:~:text=About%2023%2C690%20new%20cases%20of it's%20extremely%20rare%20in%20children"},{"key":"e_1_3_7_3_1","unstructured":"NIH. Cancer stat facts: leukemia \u2014 chronic lymphocytic leukemia (CLL). 2025 [cited 2025 Aug 5]. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/clyl.html"},{"key":"e_1_3_7_4_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.086066"},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-016-0257-2"},{"key":"e_1_3_7_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701724785"},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2024.2331631"},{"key":"e_1_3_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bneo.2024.100047"},{"key":"e_1_3_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.09.019"},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.1946"},{"key":"e_1_3_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2023.101602"},{"key":"e_1_3_7_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12254-025-01031-w"},{"key":"e_1_3_7_13_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.185868"},{"key":"e_1_3_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00293-5"},{"key":"e_1_3_7_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388"},{"key":"e_1_3_7_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009617"},{"key":"e_1_3_7_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.12057"},{"key":"e_1_3_7_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17152592"},{"key":"e_1_3_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104428"},{"key":"e_1_3_7_20_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17050799"},{"key":"e_1_3_7_21_1","unstructured":"ICON. Integrated dataverse and source solutions 2025. [cited 2025 Aug 5]. Available from: https:\/\/www.iconplc.com\/solutions\/real-world-intelligence\/symphony-health\/integrated-dataverse-and-source-solutions"},{"key":"e_1_3_7_22_1","first-page":"A574","article-title":"Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors in the U.S. - a population-based study","volume":"12","author":"Hayes K","year":"2024","unstructured":"Hayes K, Amar K, Fahim M, et al. Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors in the U.S. - a population-based study. J Immunother Cancer. 2024;12:A574\u2013A575.","journal-title":"J Immunother Cancer"},{"key":"e_1_3_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2024.03.1880"},{"key":"e_1_3_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2023.03.708"},{"key":"e_1_3_7_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000182534.19832.83"},{"key":"e_1_3_7_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-174915"},{"key":"e_1_3_7_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-201206"},{"key":"e_1_3_7_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.e23264"},{"issue":"10","key":"e_1_3_7_29_1","first-page":"S37","article-title":"Treatment adherence and persistence among patients with chronic lymphocytic leukemia\/qsmall lymphocytic lymphoma receiving first-line Bruton tyrosine kinase inhibitors","volume":"30","author":"Majd Z","year":"2024","unstructured":"Majd Z, Cheng N, Manthena S, et al., Treatment adherence and persistence among patients with chronic lymphocytic leukemia\/qsmall lymphocytic lymphoma receiving first-line Bruton tyrosine kinase inhibitors. J Managed Care Specialty Pharm. 2024;30(10 c):S37.","journal-title":"J Managed Care Specialty Pharm"},{"key":"e_1_3_7_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e19022"},{"key":"e_1_3_7_31_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2024.30.5.430"},{"key":"e_1_3_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.04.1614"},{"key":"e_1_3_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.carage.2015.10.008"},{"key":"e_1_3_7_34_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S337495"},{"key":"e_1_3_7_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000852160.44317.bf"},{"key":"e_1_3_7_36_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16152732"},{"key":"e_1_3_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2023.03.010"},{"key":"e_1_3_7_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.34_suppl.41"}],"container-title":["Expert Review of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17474086.2026.2628534","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T13:57:13Z","timestamp":1777903033000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17474086.2026.2628534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,14]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,4]]}},"alternative-id":["10.1080\/17474086.2026.2628534"],"URL":"https:\/\/doi.org\/10.1080\/17474086.2026.2628534","relation":{},"ISSN":["1747-4086","1747-4094"],"issn-type":[{"value":"1747-4086","type":"print"},{"value":"1747-4094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,14]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-12-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}